Andrew Witty is the CEO and Director of pharmaceutical company Glaxo Smith Kline and was paid £2.03 million in 2010.  He is also a board member of the Pharmaceutical Research and Manufacturers of America (PhRMA). Both Glaxo Smith Kline and PhRMA are represented on the American Legislative Exchange Council (ALEC).
Ties to American Legislative Exchange Council
ALEC is a corporate bill mill. It is not just a lobby or a front group; it is much more powerful than that. Through ALEC, corporations hand state legislators their wishlists to benefit their bottom line. Corporations fund almost all of ALEC's operations. They pay for a seat on ALEC task forces where corporate lobbyists and special interest reps vote with elected officials to approve “model” bills. Learn more at the Center for Media and Democracy's ALECexposed.org, and check out breaking news on our PRWatch.org site.
Before becoming CEO in 2008, Witty was the President of Pharmaceuticals Europe.
GlaxoSmithKline (GSK) is an international pharmaceutical giant headquartered in Britain. Various entities, including Burroughs Wellcome & Company, Smith-Kline & French Laboratories and Glaxo Laboratories merged to form GSK.  GSK is one of the top five drug firms in the world.
In the fiscal year ending in December of 2010, the company earned a total revenues of approximately $28.4 billion dollars and employed 99,913 workers.  Its CEO, Andrew Witty, made an annual compensation of $2.3 GB in 2010.
Articles and resources
Related SourceWatch articles
|This article is a stub. You can help by expanding it.|